Blog
RSS FeedPosted by Michael Wonder on 29 Oct 2020
The regions have applied for a price change for Cimzia and Simponi
29 October 2020 - The regions have submitted an application for a price change for Cimzia (certolizumab pegol) and Simponi (golimumab). ...
Posted by Michael Wonder on 28 Oct 2020
TLV reconsiders the subsidy of Cosentyx
28 October 2020 - TLV starts a reconsideration to investigate the current subsidy status for Cosentyx. ...
Posted by Michael Wonder on 26 Oct 2020
TLV is reconsidering the subsidy for hepatitis C drugs with side agreements
23 October 2020 - The current side agreements for hepatitis C drugs signed by the companies and the regions expire in ...
Posted by Michael Wonder on 24 Oct 2020
New cancer treatment with the precision drug Vitrakvi is included in the high-cost protection
23 October 2020 - For the first time in Sweden, a cancer drug against a specific genetic change, instead of against ...
Posted by Michael Wonder on 23 Oct 2020
TLV reconsiders the subsidy of Rinvoq
23 October 2020 - TLV starts a reconsideration of the current subsidy status for Rinvoq. ...
Posted by Michael Wonder on 12 Oct 2020
Ambrisentan, diazepam and dexamethasone new exchange groups
9 October 2020 - From November, ambrisentan 5 mg & 10 mg tablets, diazepam,10 mg tablets and dexamethasone 1 mg/mL ...
Posted by Michael Wonder on 30 Sep 2020
Saxenda is not included in the high-cost protection
29 September 2020 - Liraglutide (Saxenda), which is intended for weight control in adult patients with obesity or are overweight, ...
Posted by Michael Wonder on 29 Sep 2020
Epidyolex oral solution is not included in the high-cost protection
29 September 2020 - On 28 September 2020, it was decided that Epidyolex is not included in the high-cost protection. ...
Posted by Michael Wonder on 26 Sep 2020
Medicines for haemophilia remain in the high-cost protection after TLV's reconsideration
25 September 2020 - The costs of factor IX concentrate, which is used in the treatment of haemophilia B, are reduced ...
Posted by Michael Wonder on 23 Sep 2020
More patients will have access to medicines within the high-cost protection
23 September 2020 - From 2 June 2020, patients who pick up prescription drugs at pharmacies can switch to an ...
Posted by Michael Wonder on 21 Sep 2020
The next step in TLV's review of pricing of stock preparations
21 September 2020 - In the process of reviewing the pricing of stock preparations, TLV contacted the pharmaceutical companies concerned during ...
Posted by Michael Wonder on 06 Sep 2020
Venclyxto in combination with obinutuzumab is included in the high-cost protection with limitation
28 August 2020 - Venclyxto (venetoclax) is already included in the high-cost protection with limited subsidy. ...
Posted by Michael Wonder on 02 Sep 2020
Namuscla is granted a temporary subsidy
1 September 2020 - TLV has decided that Namuscla 167 mg capsules will be included in the high-cost protection until ...
Posted by Michael Wonder on 01 Sep 2020
Emgality is included in the high-cost protection with limitation
1 September 2020 - Emgality (galcanezumab), which is a preventive drug treatment for migraines, is included in the high-cost protection with ...
Posted by Michael Wonder on 01 Sep 2020
New formulation of Entyvio is included in the high-cost protection with limitation
1 September 2020 - Entyvio (vedolizumab) in the new dosage form of a solution for subcutaneous injection is included in the ...